Traces of anti-VEGF drugs found in breast milk

Anti-vascular endothelial growth factor (anti-VEGF) drugs have been identified in breast milk, prompting warnings from the researchers that the use of these medications during breastfeeding could affect developing infants. Read more

FDA clears Novartis’ new treatment for nAMD

Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the drug’s comparable results in head-to-head trials with Eylea. Read more

Investors take note of Opthea’s potential

Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate OPT-302 in FY20, as it moves closer to imposing itself on the macular disease market. Read more